Literature DB >> 15302067

Superior vena cava reconstruction using heterologous pericardial tube after extended resection for lung cancer.

Lorenzo Spaggiari1, Giulia Veronesi, Massimiliano D'Aiuto, Antonella Tosoni.   

Abstract

Superior vena cava (SVC) resection for lung cancer is feasible in selected patients, but the type of vessel reconstruction is still object of debate. We report a case of SVC revascularization successfully performed with heterologous 'custom-made' pericardial tube. This type of revascularization may improve the reconstruction of large mediastinal veins after their resection for malignancies.

Entities:  

Mesh:

Year:  2004        PMID: 15302067     DOI: 10.1016/j.ejcts.2004.05.021

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Laparoscopic pancreaticoduodenectomy with reconstruction of the mesentericoportal vein with the parietal peritoneum and the falciform ligament.

Authors:  Safi Dokmak; Béatrice Aussilhou; Mélanie Calmels; Houcine Maghrebi; Fadhel Samir Ftériche; Olivier Soubrane; Alain Sauvanet
Journal:  Surg Endosc       Date:  2018-01-18       Impact factor: 4.584

Review 2.  [Progress on the Therapeutic Approaches for Malignant Tumor 
with Superior Vena Cava Syndrome].

Authors:  Xiangzheng Liu; Shijie Zhang; Jian Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-11-20

Review 3.  A review of venous reconstruction options for the mediastinum.

Authors:  Kostantinos P Poulikidis; Jon O Wee
Journal:  Mediastinum       Date:  2022-09-25

4.  Superior vena cava replacement combined with venovenous shunt for lung cancer and thymoma: a case series.

Authors:  Wei Dai; Jifu Dong; Hongwei Zhang; Xiaojun Yang; Qiang Li
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  Thoracic tumor resection combined with SVC replacement using autologous pericardium.

Authors:  Sicong Jiang; Hao Hu; Changying Guo; Feng Jiang; Xi Liu; Lang Tang; Jianjun Tang; Xiaoliang Cheng
Journal:  World J Surg Oncol       Date:  2019-12-21       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.